← Back to Patent Explorer
US5169854A Expired / Lapsed US ⏱️ 0.0 years remaining

N-substituted-furylalkenyl hydroxamic acid and N-hydroxyurea compounds having lipoxygenase inhibitory activity

Assignee: Abbott Laboratories
•
Filing: 1992-02-26
•
Granted: 1992-12-08
•
Expires: 2012-02-26
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Compounds useful in inhibiting the biosynthesis of leukotrienes have the structure ##STR1## where M is hydrogen, a pharmaceutically acceptable cation, or a metabolically cleavable group, R 4 is alkyl, cycloalkyl or --NR 5 R 6 , where R 5 and R 6 are hydrogen, alkyl, cycloalkyl or alkanoyl, where A is a valence bond or is a straight or branched divalent alkylene group of from one to twelve carbon atoms, R 2 and R 3 are independently selected from hydrogen, straight or branched alkyl of from one to twelve carbon atoms, halogen, or trifluoroalkyl, and R 1 is selected from phenoxy, phenylthio, 2-, 3-, or 4-pyridyloxy, 1 or 2-naphthyloxy, or 2,4,5, or 8-quinolyloxy, all optionally substituted with alkyl, haloalkyl, alkoxy, hydroxy or halogen.

Inventors

  • 👤 Dee W. Brooks
  • 👤 Andrew O. Stewart
  • 👤 Pramila Bhatia
  • 👤 Richard A. Craig

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-01 13:31
CPC Classifications
C; C07; C07D; C07D405/00; C07D405/02; C07D405/12; A; A61; A61P; A61P43/00; C07D307/00; C07D307/02; C07D307/34; C07D307/56; C07D307/58; C07D307/64

Claims Analysis

Total Claims: 11
Claim 1
Independent Claim 465 words
A compound having the structure ##STR30## or a pharmaceutically acceptable salt thereof wherein A is a valence bond or is a straight or branched divalent alkylene group of from one to twelve carbon atoms; M is selected from the group consisting of hydrogen, a pharmaceutically acceptable cation, and a pharmaceutically acceptable metabolically cleavable group; R 1 is selected from the group consisting of phenoxy, optionally substituted with alkyl of from one to six carbon atoms, haloalkyl of from one to six carbon atoms, alkoxy of from one to six carbon atoms, hydroxy or halogen; phenyl-thio, optionally substituted with alkyl of from one to six carbon atoms, haloalkyl of from one to six carbon atoms, alkoxy of from one to six carbon atoms, hydroxy or halogen; 2-,3-, or 4-pyridyloxy, optionally substituted with alkyl of from one to six carbon atoms, haloalkyl of from one to six carbon atoms, alkoxy of from one to six carbon atoms, hydroxy or halogen; 2-,3-, or 4-pyridylmethoxy, optionally substituted with alkyl of from one to six carbon atoms, haloalkyl of from one to six carbon atoms, alkoxy of from one to six carbon atoms, hydroxy or halogen; 1, or 2-naphthyloxy, optionally substituted with alkyl of from one to six carbon atoms, haloalkyl of from one to six carbon atoms, alkoxy of from one to six carbon atoms, hydroxy or halogen; 2-,4-,5-, or 8-quinolyloxy, optionally substituted with alkyl of from one to six carbon atoms, haloalkyl of from one to six carbon atoms, alkoxy of from one to six carbon atoms, hydroxy or halogen; and 2-,4-,5-, or 8-quinolylmethoxy, optionally substituted with alkyl of from one to six carbon atoms, haloalkyl of from one to six carbon atoms, alkoxy of from one to six carbon atoms, hydroxy or halogen; R 2 and R 3 are independently selected from the group consisting of hydrogen, alkyl of from one to twelve carbon atoms, halogen, and trifluoroalkyl; R 4 is selected from the group consisting of hydrogen, alkyl of from one to twelve carbon atoms, cycloalkyl of from three to eight carbon atoms, and --NR 5 R 6 where R 5 is selected from the group consisting of hydrogen, alkyl of from one to six carbon atoms, hydroxyalkyl of from one to six carbon atoms, and alkoxyalkyl in which the alkoxy portion and the alkyl portion each contain, independently, from one to six carbon atoms, and R 6 is selected from the group consisting of hydrogen, alkyl of from one to six carbon atoms, hydroxyalkyl of from one to six carbon atoms, alkoxyalkyl in which the alkoxy portion and the alkyl portion each contain, independently, from one to six carbon atoms, alkanoyl of from two to eight carbon atoms, carbocyclic aryl, and (carbocyclic aryl)alkyl in which the alkyl portion contains from one to six carbon atoms.
Claim 2
Dependent Claim 465 words
A compound having the structure ##STR30## or a pharmaceutically acceptable salt thereof wherein A is a valence bond or is a straight or branched divalent alkylene group of from one to twelve carbon atoms; M is selected from the group consisting of hydrogen, a pharmaceutically acceptable cation, and a pharmaceutically acceptable metabolically cleavable group; R 1 is selected from the group consisting of phenoxy, optionally substituted with alkyl of from one to six carbon atoms, haloalkyl of from one to six carbon atoms, alkoxy of from one to six carbon atoms, hydroxy or halogen; phenyl-thio, optionally substituted with alkyl of from one to six carbon atoms, haloalkyl of from one to six carbon atoms, alkoxy of from one to six carbon atoms, hydroxy or halogen; 2-,3-, or 4-pyridyloxy, optionally substituted with alkyl of from one to six carbon atoms, haloalkyl of from one to six carbon atoms, alkoxy of from one to six carbon atoms, hydroxy or halogen; 2-,3-, or 4-pyridylmethoxy, optionally substituted with alkyl of from one to six carbon atoms, haloalkyl of from one to six carbon atoms, alkoxy of from one to six carbon atoms, hydroxy or halogen; 1, or 2-naphthyloxy, optionally substituted with alkyl of from one to six carbon atoms, haloalkyl of from one to six carbon atoms, alkoxy of from one to six carbon atoms, hydroxy or halogen; 2-,4-,5-, or 8-quinolyloxy, optionally substituted with alkyl of from one to six carbon atoms, haloalkyl of from one to six carbon atoms, alkoxy of from one to six carbon atoms, hydroxy or halogen; and 2-,4-,5-, or 8-quinolylmethoxy, optionally substituted with alkyl of from one to six carbon atoms, haloalkyl of from one to six carbon atoms, alkoxy of from one to six carbon atoms, hydroxy or halogen; R 2 and R 3 are independently selected from the group consisting of hydrogen, alkyl of from one to twelve carbon atoms, halogen, and trifluoroalkyl; R 4 is selected from the group consisting of hydrogen, alkyl of from one to twelve carbon atoms, cycloalkyl of from three to eight carbon atoms, and --NR 5 R 6 where R 5 is selected from the group consisting of hydrogen, alkyl of from one to six carbon atoms, hydroxyalkyl of from one to six carbon atoms, and alkoxyalkyl in which the alkoxy portion and the alkyl portion each contain, independently, from one to six carbon atoms, and R 6 is selected from the group consisting of hydrogen, alkyl of from one to six carbon atoms, hydroxyalkyl of from one to six carbon atoms, alkoxyalkyl in which the alkoxy portion and the alkyl portion each contain, independently, from one to six carbon atoms, alkanoyl of from two to eight carbon atoms, carbocyclic aryl, and (carbocyclic aryl)alkyl in which the alkyl portion contains from one to six carbon atoms.
Claim 3
Dependent Claim 35 words
A compound as defined by claim 1 or pharmaceutically acceptable salt thereof wherein R 4 is selected from alkyl of from one to twelve carbon atoms and cycloalkyl of from three to eight carbon atoms.
Claim 4
Dependent Claim 25 words
A compound as defined by claim 1 wherein R 4 is --NR 5 R 6 where R 5 and R 6 are as defined therein.
Claim 5
Dependent Claim 35 words
A compound as defined by claim 3 having the structure ##STR31## wherein A, R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are as defined therein.
Claim 6
Dependent Claim 12 words
The compound having the name E-N-[4-(5-(4-fluorophenoxy)-2-furanyl)but-3-en-2-yl]-N-hydroxyurea or a pharmaceutically acceptable salt thereof.
Claim 7
Dependent Claim 12 words
The compound having the name E-N-[4-(5-(4-fluorophenoxy)-2-furanyl)but-3-en-2-yl]-N-hydroxyurea or a pharmaceutically acceptable salt thereof.
Claim 8
Dependent Claim 41 words
A compound, or pharmaceutically acceptable salt thereof, selected from the group consisting of E-N-[3-(5-phenoxy-2-furanyl)-2-propen-1-yl]-N-hydroxyurea; Z-N-[4-(5-(4-fluorophenoxy)-2-furanyl)-2-fluorobut-3-en-2-yl]-N-hydroxyurea E-N-[4-(5-phenoxy-2-furanyl)but-3-en-2-yl]-N-hydroxyurea; E-N-[4-(5-(2-fluorophenoxy)-2-furanyl)but-3-en-2-yl]-N-hydroxyurea; E-N-[4-(5-(2,4-difluorophenoxy)-2-furanyl)but-3-en-2-yl]-N-hydroxyurea; E-N-[4-(5-(2-methyl-4-fluorophenoxy)-2-furanyl)but-3-en-2-yl]-N-hydroxyurea; E-N-[4-(5-(4-chlorophenoxy)-2-furanyl)but-3-en-2-yl]-N-hydroxyurea; E-N-[4-(5-(4-bromophenoxy)-2-furanyl)but-3-en-2-yl]-N-hydroxyurea; E-N-[4-(5-(4-n-butoxyphenoxy)-2-furanyl)but-3-en-2-yl]-N-hydroxyurea; E-N-[4-(5-(4-n-butylphenoxy)-2-furanyl)but-3-en-2-yl]-N-hydroxyurea; E-N-[4-(5-(4-thiomethylphenoxy)-2-furanyl)but-3-en-2-yl]-N-hydroxyurea; E-N-[4-(5-(4-cyanophenoxy)-2-furanyl)but-3-en-2-yl]-N-hydroxyurea; E-N-[4-(5-(4-fluorophenoxy)-3-methyl-2-furanyl)but-3-en-2-yl]-N-hydroxyurea; E-N-[4-(5-(2-naphthoxy)-2-furanyl)but-3-en-2-yl]-N-hydroxyurea; E-N-[4-(5-quinolyloxy-2-furanyl)but-3-en-2-yl]-N-hydroxyurea; E-N-[4-(5-(4-fluorothiophenoxy)-2-furanyl)but-3-en-2-yl]-N-hydroxyurea; E-N-[4-(5-(4-thiophenoxy)-2-furanyl)but-3-en-2-yl]-N-hydroxyurea; E-N-[4-(5-(3-pyridnyloxy)but-3-ene-2-yl]-N-hydroxyurea; E-N-[4-(5-(6-methyl-3-pyridnyloxy)-2-furanyl)but-3-en-2-yl]-N-hydroxyurea; E-N-[4-(5-(5-chloro-3-pyridnyloxy)-2-furanyl)but-3-en-2-yl]-N-hydroxyurea; E-N-[4-(5-(2-mercaptopyridinyl)-2-furanyl)but-3-en-2-yl]-N-hydroxyurea; E-N-[4-(5-(4-fluorophenoxy)-2-furanyl)but-3-en-2-yl]-N-hydroxyacetamide; E-N-[3-(5-phenoxy-2-furanyl)-2-propenyl]-N-hydroxyacetamide; E-N-[4-(5-(2,4-difluorophenoxy)-2-furanyl)but-3-en-2-yl]-N-hydroxyacetamide; E-N-[4-(5-(4-n-butoxyphenoxy)-2-furanyl)but-3-en-2-yl]-N-hydroxyacetamide; E-N-[4-(5-(4-fluorothiophenoxy)-2-furanyl)but-3-en-2-yl]-N-hydroxyacetamide; and E-N-4-(5-(3-pyridyloxy)-2-furanyl)but-3-en-2-yl]-N-hydroxyacetamide.
Claim 9
Dependent Claim 41 words
A compound, or pharmaceutically acceptable salt thereof, selected from the group consisting of E-N-[3-(5-phenoxy-2-furanyl)-2-propen-1-yl]-N-hydroxyurea; Z-N-[4-(5-(4-fluorophenoxy)-2-furanyl)-2-fluorobut-3-en-2-yl]-N-hydroxyurea E-N-[4-(5-phenoxy-2-furanyl)but-3-en-2-yl]-N-hydroxyurea; E-N-[4-(5-(2-fluorophenoxy)-2-furanyl)but-3-en-2-yl]-N-hydroxyurea; E-N-[4-(5-(2,4-difluorophenoxy)-2-furanyl)but-3-en-2-yl]-N-hydroxyurea; E-N-[4-(5-(2-methyl-4-fluorophenoxy)-2-furanyl)but-3-en-2-yl]-N-hydroxyurea; E-N-[4-(5-(4-chlorophenoxy)-2-furanyl)but-3-en-2-yl]-N-hydroxyurea; E-N-[4-(5-(4-bromophenoxy)-2-furanyl)but-3-en-2-yl]-N-hydroxyurea; E-N-[4-(5-(4-n-butoxyphenoxy)-2-furanyl)but-3-en-2-yl]-N-hydroxyurea; E-N-[4-(5-(4-n-butylphenoxy)-2-furanyl)but-3-en-2-yl]-N-hydroxyurea; E-N-[4-(5-(4-thiomethylphenoxy)-2-furanyl)but-3-en-2-yl]-N-hydroxyurea; E-N-[4-(5-(4-cyanophenoxy)-2-furanyl)but-3-en-2-yl]-N-hydroxyurea; E-N-[4-(5-(4-fluorophenoxy)-3-methyl-2-furanyl)but-3-en-2-yl]-N-hydroxyurea; E-N-[4-(5-(2-naphthoxy)-2-furanyl)but-3-en-2-yl]-N-hydroxyurea; E-N-[4-(5-quinolyloxy-2-furanyl)but-3-en-2-yl]-N-hydroxyurea; E-N-[4-(5-(4-fluorothiophenoxy)-2-furanyl)but-3-en-2-yl]-N-hydroxyurea; E-N-[4-(5-(4-thiophenoxy)-2-furanyl)but-3-en-2-yl]-N-hydroxyurea; E-N-[4-(5-(3-pyridnyloxy)but-3-ene-2-yl]-N-hydroxyurea; E-N-[4-(5-(6-methyl-3-pyridnyloxy)-2-furanyl)but-3-en-2-yl]-N-hydroxyurea; E-N-[4-(5-(5-chloro-3-pyridnyloxy)-2-furanyl)but-3-en-2-yl]-N-hydroxyurea; E-N-[4-(5-(2-mercaptopyridinyl)-2-furanyl)but-3-en-2-yl]-N-hydroxyurea; E-N-[4-(5-(4-fluorophenoxy)-2-furanyl)but-3-en-2-yl]-N-hydroxyacetamide; E-N-[3-(5-phenoxy-2-furanyl)-2-propenyl]-N-hydroxyacetamide; E-N-[4-(5-(2,4-difluorophenoxy)-2-furanyl)but-3-en-2-yl]-N-hydroxyacetamide; E-N-[4-(5-(4-n-butoxyphenoxy)-2-furanyl)but-3-en-2-yl]-N-hydroxyacetamide; E-N-[4-(5-(4-fluorothiophenoxy)-2-furanyl)but-3-en-2-yl]-N-hydroxyacetamide; and E-N-4-(5-(3-pyridyloxy)-2-furanyl)but-3-en-2-yl]-N-hydroxyacetamide.
Claim 10
Dependent Claim 29 words
A pharmaceutical composition for inhibiting the biosynthesis of leukotrienes comprising a therapeutically effective amount of a compound as defined by claim 1 in combination with a pharmaceutically acceptable carrier.
Claim 11
Dependent Claim 28 words
A method of inhibiting the biosynthesis of leukotrienes comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of claim 1.

References Cited (Backward Citations)

US4097487A Cited
US4738986A Cited
US4769461A Cited
EP0292699A2 Cited
EP0299761A1 Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1995-12-08 1996-06-08 1996-12-08 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1999-12-08 2000-06-08 2000-12-08 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2003-12-08 2004-06-08 2004-12-08 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag